scholarly journals KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib

2011 ◽  
Vol 25 (4) ◽  
Author(s):  
Sonnemann
2015 ◽  
Vol 10 (2) ◽  
pp. 126-130
Author(s):  
Yong Tian ◽  
Cong Chen ◽  
Yu Zhang ◽  
Zhen Zhang ◽  
Haiyan Xie

Sign in / Sign up

Export Citation Format

Share Document